文献速递血液净化与透析

维持性血透患者铁剂给药策略比较:随机对照试验

Comparison of Iron Dosing Strategies in Patients Undergoing Long-Term Hemodialysis: A Randomized Controlled Trial.
PubMed 文献 · Clin J Am Soc Nephrol · 2021-09-01

本研究为开放标签、随机对照非劣效性试验,纳入142例维持性血透患者,比较每2周100mg蔗糖铁连续20次与每10周500mg羧基麦芽糖铁共4次(总铁量2g)对血红蛋白的影响。40周时羧基麦芽糖糖铁组血红蛋白下降更明显,非劣效性未成立。

要点

  • 低频大剂量羧基麦芽糖铁在维持血红蛋白方面未能证明非劣效于高频低剂量蔗糖铁。
  • 羧基麦芽糖铁组铁蛋白和转铁蛋白饱和度下降幅度大于蔗糖铁组。
  • 两组促红细胞生成素用量无差异,总体不良事件相似,蔗糖铁组感染更多。

核心结论

  • 等累积剂量下,低频羧基麦芽糖铁未能达到维持血红蛋白的非劣效性。

研究设计与样本

  • 开放标签、随机对照非劣效性试验,纳入142例维持性血透患者,干预40周。
  • 蔗糖铁组:每2周100mg连续20次;羧基麦芽糖铁组:每10周500mg共4次,总铁量均为2g。
  • 主要终点为第40周血红蛋白较基线的变化,非劣效界值为-0.8 g/dl。

主要发现

  • 蔗糖铁组血红蛋白变化为-0.27 g/dl(95%CI -0.64至0.09),羧基麦芽糖铁组为-0.74 g/dl(95%CI -1.1至-0.39)。
  • 符合方案人群中,羧基麦芽糖铁组较蔗糖铁组血红蛋白变化差异为-0.47 g/dl(95%CI -0.95至0.01),非劣效性未成立。
  • 第40周较基线比例变化:铁蛋白差异-31%(98.3%CI -52至-0.1),转铁蛋白差异1%(98.3%CI -7至10),转铁蛋白饱和度差异-27%(98.3%CI -39至-13)。
  • 促红细胞生成素用量两组无差异;总体不良事件相似,但蔗糖铁组感染更多。

临床怎么用

  • 对于维持性血透患者的贫血管理,高频低剂量蔗糖铁方案在维持血红蛋白方面可能优于低频大剂量羧基麦芽糖铁。
  • 选择铁剂给药策略时需考虑铁蛋白和转铁蛋白饱和度的下降风险。

局限性

  • 开放标签设计可能引入偏倚。
  • 样本量较小(142例随机,108例完成),可能影响结果稳健性。
  • 非劣效性未成立可能受限于非劣效界值设定和统计效力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Whether iron supplementation in patients on hemodialysis could be delivered by less frequent but higher single doses compared with the currently more common higher-frequency schedules of lower single iron doses is unknown. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We carried out an open-label, randomized, controlled noninferiority trial over 40 weeks in patients on prevalent hemodialysis (n=142). We administered in total 2 g iron as 100 mg iron sucrose biweekly in a continuous (20 × 100 mg) fashion or 500 mg ferric carboxymaltose every 10 weeks in a periodic (4 × 500 mg) fashion. The primary end point was the change in hemoglobin at week 40 from baseline with a noninferiority margin of -0.8 g/dl. Secondary end points were changes in ferritin, transferrin, transferrin saturation, and erythropoiesis-stimulating agent use. RESULTS: In total, 108 patients completed the study. At 40 weeks, hemoglobin changed by -0.27 g/dl (95% confidence interval, -0.64 to 0.09) in the iron sucrose arm and by -0.74 g/dl (95% confidence interval, -1.1 to -0.39) in the ferric carboxymaltose arm compared with baseline. Noninferiority was not established in the per-protocol population as hemoglobin changes compared with baseline differed by -0.47 g/dl (95% confidence interval, -0.95 to 0.01) in the ferric carboxymaltose arm compared with the iron sucrose arm. Proportional changes from baseline to week 40 differed by -31% (98.3% confidence interval, -52 to -0.1) for ferritin, by 1% (98.3% confidence interval, -7 to 10) for transferrin, and by -27% (98.3% confidence interval, -39 to -13) for transferrin saturation in the ferric carboxymaltose arm compared with the iron sucrose arm. Erythropoiesis-stimulating agent dosing did not differ between groups. The overall number of adverse events was similar; however, more infections were observed in the iron sucrose arm. CONCLUSIONS: An equal cumulative dose of ferric carboxymaltose administered less frequently did not meet noninferiority for maintaining hemoglobin levels compared with iron sucrose administered more frequently. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Comparison Study of Two Iron Compounds for Treatment of Anemia in Hemodialysis Patients (COPEFER), NCT02198495.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Bielesz B, Lorenz M, Monteforte R, et al. Comparison of Iron Dosing Strategies in Patients Undergoing Long-Term Hemodialysis: A Randomized Controlled Trial. Clin J Am Soc Nephrol. 2021. PMID: 34470831. doi:10.2215/CJN.03850321

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。